azilsartan medoxomil

Your question

Ask in your own words. Each question is answered independently.

Explore sample questions

Select a question to fill the editor, then ask it or make it your own.

DrugCentral answer

Your answer will appear here. Open linked drug cards in a new tab to explore the source details.

About Ask DrugCentral

Ask DrugCentral helps you explore drug properties, biological targets, and indications using natural language. Sample questions offer starting points, and linked drug cards let you check the underlying records.

General architecture

Ask a questionThe browser sends your question to the same-origin Django chat API.
Retrieve and generateThe API forwards the question to the configured DrugCentral retrieval-augmented generation (RAG) service, which returns an AI-generated answer.
Explore the answerThe app resolves cited drug-card names and displays the answer with links to drug records.

Using the assistant

Each request is independent; previous questions are not sent as conversation history. You can edit a sample before submitting, retry a failed request, or switch back to normal search. Drug links open in a new tab so your question and answer stay available.

Answers may contain mistakes or omit information. Verify details against DrugCentral records and original sources.

Property	Description	Value
kinase-safety-class	ACVR2A,ACVR2B,AURKA,AXL,BRAF,BTK,CAMK2D,CDK5,CDK9,DDR1,DYRK1B,EIF2AK3,ERBB2,GRK2,GSK3B,ITK,JAK2,MAP3K21,MAP3K7,MAPK7,MAPK9,MAPKAPK2,MARK4,MET,NTRK2,PDK1,PDK2,PDK4,PDPK1,PIK3CB,PIK3CD,PRKDC,STK33,TEK,TTK	35
kinase-selectivity-class	AXL,GRK2,MAP2K6,TEK	4
pfas-class	PFAS structural alert (1 = True, 0 = False)	0

Date	Agency	Company
Feb. 25, 2011	FDA	ARBOR PHARMS IRELAND
Dec. 7, 2011	EMA	Takeda Pharma A/S
Jan. 18, 2001	PMDA	TAKEDA PHARMACEUTICAL COMPANY LIMITED

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Renal impairment	105.51	24.20	59	3301	105362	90519725
Platelet count decreased	88.76	24.20	58	3302	136911	90488176
Hepatic function abnormal	78.52	24.20	37	3323	46251	90578836
Cerebral infarction	73.57	24.20	30	3330	26566	90598521
Hyperkalaemia	50.74	24.20	31	3329	64933	90560154
Decreased appetite	46.26	24.20	63	3297	376477	90248610
Interstitial lung disease	46.13	24.20	31	3329	76374	90548713
Cardiac failure	38.25	24.20	32	3328	109464	90515623
Proteinuria	37.58	24.20	18	3342	23273	90601814
Altered state of consciousness	35.19	24.20	19	3341	31513	90593574
Glomerular filtration rate decreased	27.05	24.20	13	3347	16919	90608168
Blood creatinine increased	26.20	24.20	25	3335	101361	90523726
Palmar-plantar erythrodysaesthesia syndrome	26.12	24.20	15	3345	28008	90597079
Malignant neoplasm progression	25.08	24.20	25	3335	106845	90518242
Blood pressure decreased	24.32	24.20	21	3339	74874	90550213

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Cerebral infarction	123.54	20.57	61	4230	31108	42585936
Renal impairment	103.92	20.57	87	4204	110141	42506903
Hepatic function abnormal	85.08	20.57	57	4234	51510	42565534
Interstitial lung disease	69.87	20.57	60	4231	78402	42538642
Fibrillary glomerulonephritis	48.64	20.57	8	4283	59	42616985
Proteinuria	46.72	20.57	29	4262	22954	42594090
Decreased appetite	44.70	20.57	74	4217	193063	42423981
Pemphigoid	38.24	20.57	20	4271	11447	42605597
Palmar-plantar erythrodysaesthesia syndrome	36.92	20.57	24	4267	20558	42596486
Altered state of consciousness	35.83	20.57	27	4264	29232	42587812
Cardiac failure	31.74	20.57	46	4245	106810	42510234
Nephrotic syndrome	31.35	20.57	16	4275	8702	42608342
Thalamus haemorrhage	30.55	20.57	9	4282	1110	42615934
Thrombotic cerebral infarction	28.05	20.57	7	4284	462	42616582
Hyperkalaemia	27.40	20.57	37	4254	80421	42536623
Hepatocellular carcinoma	26.49	20.57	14	4277	8180	42608864
Liver disorder	24.91	20.57	25	4266	39619	42577425
Cerebral haemorrhage	23.44	20.57	24	4267	38942	42578102
Intestinal ischaemia	22.04	20.57	13	4278	9375	42607669
Hyperuricaemia	21.99	20.57	13	4278	9411	42607633
Blood pressure decreased	21.66	20.57	28	4263	58304	42558740
Gastric ulcer haemorrhage	21.32	20.57	11	4280	6116	42610928
Gastrointestinal hypomotility	21.03	20.57	7	4284	1286	42615758
Fulminant type 1 diabetes mellitus	20.61	20.57	7	4284	1367	42615677

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Renal impairment	193.87	18.06	136	7706	188309	110393148
Cerebral infarction	189.23	18.06	86	7756	51752	110529705
Hepatic function abnormal	155.66	18.06	90	7752	89205	110492252
Interstitial lung disease	114.71	18.06	88	7754	139246	110442211
Decreased appetite	79.68	18.06	130	7712	475716	110105741
Proteinuria	79.56	18.06	44	7798	39974	110541483
Platelet count decreased	76.83	18.06	88	7754	230355	110351102
Altered state of consciousness	69.56	18.06	46	7796	57580	110523877
Hyperkalaemia	68.95	18.06	65	7777	135731	110445726
Cardiac failure	64.80	18.06	73	7769	187553	110393904
Palmar-plantar erythrodysaesthesia syndrome	55.04	18.06	35	7807	40990	110540467
Thalamus haemorrhage	50.70	18.06	14	7828	1950	110579507
Fibrillary glomerulonephritis	50.22	18.06	8	7834	70	110581387
Pemphigoid	48.54	18.06	25	7817	19682	110561775
Malignant neoplasm progression	47.23	18.06	60	7782	174507	110406950
Blood pressure decreased	45.31	18.06	48	7794	115043	110466414
Thrombotic cerebral infarction	41.86	18.06	10	7832	784	110580673
Cerebral haemorrhage	38.62	18.06	34	7808	64934	110516523
Nephrotic syndrome	38.32	18.06	19	7823	13812	110567645
Aortic dissection	38.01	18.06	14	7828	4919	110576538
Hyperuricaemia	37.43	18.06	19	7823	14512	110566945
Glomerular filtration rate decreased	34.65	18.06	23	7819	28933	110552524
Hypothyroidism	33.39	18.06	33	7809	72866	110508591
Dehydration	33.35	18.06	66	7776	279445	110302012
Liver disorder	32.46	18.06	45	7797	142198	110439259
Fulminant type 1 diabetes mellitus	31.06	18.06	10	7832	2353	110579104
Pyelonephritis	30.08	18.06	20	7822	25230	110556227
Sinus node dysfunction	29.81	18.06	14	7828	9033	110572424
Hepatocellular carcinoma	28.64	18.06	14	7828	9866	110571591
Blood creatinine increased	27.86	18.06	48	7794	182841	110398616
Renal disorder	27.63	18.06	25	7817	49454	110532003
Enterocolitis	27.50	18.06	17	7825	18932	110562525
Cholangitis	27.18	18.06	16	7826	16319	110565138
Pain	24.72	18.06	19	7823	954936	109626521
Immune-mediated enterocolitis	22.45	18.06	12	7830	10173	110571284
Anaemia	22.21	18.06	87	7755	546999	110034458
Secondary adrenocortical insufficiency	21.51	18.06	9	7833	4425	110577032
Confusional state	20.82	18.06	4	7838	468676	110112781
Urinary retention	20.50	18.06	25	7817	69658	110511799
Diarrhoea	20.26	18.06	144	7698	1139361	109442096
Rhabdomyolysis	20.19	18.06	33	7809	120368	110461089
Gastric ulcer haemorrhage	19.78	18.06	11	7831	10083	110571374
Intestinal ischaemia	19.72	18.06	13	7829	16166	110565291
Joint swelling	19.21	18.06	4	7838	442841	110138616
Pneumonia aspiration	18.97	18.06	26	7816	81207	110500250
Erythema multiforme	18.81	18.06	14	7828	21083	110560374
Dyslalia	18.72	18.06	6	7836	1391	110580066
Shunt stenosis	18.64	18.06	6	7836	1410	110580047
Haemorrhagic cerebral infarction	18.32	18.06	6	7836	1489	110579968
Spinal compression fracture	18.21	18.06	13	7829	18379	110563078

Ask DrugCentral

Your question

DrugCentral answer

About Ask DrugCentral

General architecture

Using the assistant

azilsartan medoxomil 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Description:

Drug dosage:

ADMET properties:

Predicted pharmacokinetic/toxicological properties (PK-AZ):

Approvals:

FDA Adverse Event Reporting System (Female)

FDA Adverse Event Reporting System (Male)

FDA Adverse Event Reporting System (Geriatric)

FDA Adverse Event Reporting System (Pediatric)

Pharmacologic Action:

Related Drugs by ATC class:

Drug Use | Suggest Off label Use Form| |View source of the data|

🐶 Veterinary Drug Use

🐶 Veterinary products

Acid dissociation constants calculated using MoKa v3.0.0

Orange Book patent data (new drug applications)

Orange Book exclusivity data (new drug applications)

Bioactivity Summary:

External reference:

Pharmaceutical products:

Source	Code	Description
ATC	C09CA09	CARDIOVASCULAR SYSTEM AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), PLAIN Angiotensin II receptor blockers (ARBs), plain
ATC	C09DA09	CARDIOVASCULAR SYSTEM AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), COMBINATIONS Angiotensin II receptor blockers (ARBs) and diuretics
FDA EPC	N0000175561	Angiotensin 2 Receptor Blocker
MeSH PA	D047228	Angiotensin II Type 1 Receptor Blockers
MeSH PA	D057911	Angiotensin Receptor Antagonists
FDA PE	N0000178477	Decreased Blood Pressure
FDA MoA	N0000180999	Angiotensin 2 Type 1 Receptor Antagonists
CHEBI has role	CHEBI:35554	cardiovascular drug
CHEBI has role	CHEBI:35674	antihypertensive agent
CHEBI has role	CHEBI:50266	prodrug
CHEBI has role	CHEBI:61016	angiotensin receptor antagonist
CHEBI has role	CHEBI:22587	antiviral agent
CHEBI has role	CHEBI:35526	hypoglycemic agent

Disease	Relation	SNOMED_ID	DOID
Hypertensive disorder	indication	38341003	DOID:10763
Hypovolemia	contraindication	28560003
Low blood pressure	contraindication	45007003
Hyponatremia	contraindication	89627008
Impaired renal function disorder	contraindication	197663003
Pregnancy, function	contraindication	289908002
Renal artery stenosis	contraindication	302233006

Formulation strength	Trade name	Applicant	Application number	Approval date	Type	Dose form	Route	Patent number	Patent expiration date	Patent use
EQ 40MG MEDOXOMIL;12.5MG	EDARBYCLOR	AZURITY	N202331	Dec. 20, 2011	RX	TABLET	ORAL	9387249	July 1, 2031	TREATMENT OF HYPERTENSION
EQ 40MG MEDOXOMIL;25MG	EDARBYCLOR	AZURITY	N202331	Dec. 20, 2011	RX	TABLET	ORAL	9387249	July 1, 2031	TREATMENT OF HYPERTENSION

Formulation strength	Trade name	Applicant	Application number	Approval date	Type	Dose form	Route	Exclusivity date	Description
EQ 40MG MEDOXOMIL	AZILSARTAN MEDOXOMIL	LUPIN	A214489	July 20, 2022	RX	TABLET	ORAL	Dec. 12, 2026	PATENT CHALLENGE
EQ 80MG MEDOXOMIL	AZILSARTAN MEDOXOMIL	LUPIN	A214489	July 20, 2022	RX	TABLET	ORAL	Dec. 12, 2026	PATENT CHALLENGE

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Bioact source	MoA source
Type-1 angiotensin II receptor	GPCR	P30556	AGTR1_HUMAN	ANTAGONIST	IC50	8.13	IUPHAR	CHEMBL
Type-2 angiotensin II receptor	GPCR	P50052	AGTR2_HUMAN		IC50	8.59	CHEMBL
Type-1 angiotensin II receptor	GPCR		AGTR1_BOVIN		IC50	6.38	CHEMBL

ID	Source
D08067	KEGG_DRUG
4030593	VANDF
4030594	VANDF
C2698291	UMLSCUI
CHEBI:68845	CHEBI
CHEMBL2028661	ChEMBL_ID
CHEMBL2103795	ChEMBL_ID
DB08822	DRUGBANK_ID
C557413	MESH_SUPPLEMENTAL_RECORD_UI
6900	IUPHAR_LIGAND_ID
8874	INN_ID
LL0G25K7I2	UNII
135409642	PUBCHEM_CID
1091642	RXNORM
180314	MMSL
27787	MMSL
403028	MMSL
d07754	MMSL
013661	NDDF
013662	NDDF
448917007	SNOMEDCT_US
449042005	SNOMEDCT_US
449561004	SNOMEDCT_US
C1958569	UMLSCUI
A1IPH	PDB_CHEM_ID
CHEMBL57242	ChEMBL_ID
147403-03-0	SECONDARY_CAS_RN
135415867	PUBCHEM_CID
6901	IUPHAR_LIGAND_ID
8724	INN_ID
C521273	MESH_SUPPLEMENTAL_RECORD_UI
F9NUX55P23	UNII
CHEBI:68850	CHEBI
F9NUX55P23	INXIGHT DRUGS
LL0G25K7I2	INXIGHT DRUGS

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	8.11	acidic
pKa2	3.02	Basic
pKa3	2.4	Basic